Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Solid Biosciences LLC(SLDB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SLDB
10/19/2026: SLDB (1-star) is currently NOT-A-BUY. Pass it for now.
Solid Biosciences is a clinical-stage biotechnology company developing advanced gene therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy. The company's primary strength lies in its proprietary AAV capsid platform, which it is leveraging to improve therapeutic delivery. The main investment story centers on the potential for clinical breakthroughs in its SGT-003 program and a broader pipeline expansion into cardiac indications. However, investors face risks related to a lack of commercial revenue, historical clinical volatility, and intense competition from larger industry players. This stock is best suited for high-risk growth investors who should closely monitor clinical trial updates and the company's cash management initiatives.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential linked to clinical breakthroughs but carries significant developmental risk. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp moves based on clinical data releases or regulatory updates. |
| Value investor | Weak fit | There are no earnings or cash flows to support a traditional value-based valuation model. |
| Dividend investor | Weak fit | The company is in an early growth phase and does not provide dividend income. |
| Low-risk investor | Weak fit | The high volatility associated with clinical-stage biotech makes this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are highly sensitive to news, trial data, and regulatory decisions. |
| Valuation risk | High | Valuations are often speculative and based on projected future outcomes rather than current financial health. |
| Competition risk (Gene Therapy) | Medium / high | Well-capitalized competitors have multiple products on the market or in advanced clinical stages. |
| Business quality | Medium | The company is still proving its proprietary technology platform and clinical execution. |
| Dividend income | Low / none | This is a growth-oriented company that reinvests all capital into research. |
| Execution risk | High | The complexity of gene therapy development means any technical failure can significantly impair the company. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -54.13% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 634.77M USD | Price to earnings Ratio - | 1Y Target Price 18.71 |
Price to earnings Ratio - | 1Y Target Price 18.71 | ||
Volume (30-day avg) 1.5M shares | Beta 2.47 | 52 Weeks Range 3.79 - 11.45 | Updated Date 10/19/2026 |
52 Weeks Range 3.79 - 11.45 | Updated Date 10/19/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.89 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing SGT-003 and other gene therapy candidates toward commercialization. | The company does not currently generate product revenue; it is funded by investors betting on future drug approval. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 500.82M | Price to Sales(TTM) 3.65 |
Enterprise Value 500.82M | Price to Sales(TTM) 3.65 | ||
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA -3.69 | Shares Outstanding 107.23M | Shares Floating 64.81M |
Shares Outstanding 107.23M | Shares Floating 64.81M | ||
Percent Insiders 0.68 | Percent Institutions 107.56 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.